Cargando…

The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children

Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Hyo Jin, Lee, Soo Young, Kim, Ki Hwan, Kim, Dong Soo, Cha, Sung Ho, Jo, Dae Sun, Kang, Jin Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414646/
https://www.ncbi.nlm.nih.gov/pubmed/25931793
http://dx.doi.org/10.3346/jkms.2015.30.5.612
_version_ 1782368976460840960
author Kwon, Hyo Jin
Lee, Soo Young
Kim, Ki Hwan
Kim, Dong Soo
Cha, Sung Ho
Jo, Dae Sun
Kang, Jin Han
author_facet Kwon, Hyo Jin
Lee, Soo Young
Kim, Ki Hwan
Kim, Dong Soo
Cha, Sung Ho
Jo, Dae Sun
Kang, Jin Han
author_sort Kwon, Hyo Jin
collection PubMed
description Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-4414646
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-44146462015-05-01 The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children Kwon, Hyo Jin Lee, Soo Young Kim, Ki Hwan Kim, Dong Soo Cha, Sung Ho Jo, Dae Sun Kang, Jin Han J Korean Med Sci Original Article Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe. GRAPHICAL ABSTRACT: [Image: see text] The Korean Academy of Medical Sciences 2015-05 2015-04-15 /pmc/articles/PMC4414646/ /pubmed/25931793 http://dx.doi.org/10.3346/jkms.2015.30.5.612 Text en © 2015 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kwon, Hyo Jin
Lee, Soo Young
Kim, Ki Hwan
Kim, Dong Soo
Cha, Sung Ho
Jo, Dae Sun
Kang, Jin Han
The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
title The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
title_full The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
title_fullStr The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
title_full_unstemmed The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
title_short The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
title_sort immunogenicity and safety of the live-attenuated sa 14-14-2 japanese encephalitis vaccine given with a two-dose primary schedule in children
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414646/
https://www.ncbi.nlm.nih.gov/pubmed/25931793
http://dx.doi.org/10.3346/jkms.2015.30.5.612
work_keys_str_mv AT kwonhyojin theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT leesooyoung theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT kimkihwan theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT kimdongsoo theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT chasungho theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT jodaesun theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT kangjinhan theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT kwonhyojin immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT leesooyoung immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT kimkihwan immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT kimdongsoo immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT chasungho immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT jodaesun immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren
AT kangjinhan immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren